Bosnia and Herzegovina: data sheet
Introduction
This page contains the most recent drug-related data for Bosnia and Herzegovina.
The data and information presented on this page were collected under the European Commission’s Instrument for Pre-accession Assistance (IPA) programme.
Since 2008, the European Drugs Agency (EUDA) has worked with EU candidate and potential candidates through projects funded by the Instrument for Pre-accession Assistance (IPA). In 2023, EUDA launched the IPA8 project, involving six beneficiaries—Albania, Bosnia and Herzegovina, North Macedonia, Kosovo*, Montenegro, and Serbia. The aim of the project is to prepare these countries for active participation in the EUDA and the Reitox network upon accession.
Last update: 24 April 2026
* Kosovo: this designation is without prejudice to positions on status, and is in line with UNSCR 1244/1999 and the ICJ Opinion on the Kosovo declaration of independence.
Bosnia and Herzegovina: about the data presented on this page
Bosnia and Herzegovina does not have a national drug observatory (NDO) and thus has limited capacity to carry out studies and establish a national drug information system. The IPA national correspondent is based at the Ministry of Security and has limited access to data on health.
The data presented here are reported to the EUDA by the national correspondent on an annual basis and should conform to the respective EUDA guidelines and protocols. Details on methods and definitions can be found in the EUDA Statistical Bulletin.
Prevalence and patterns of drug use
Drug use in the adult population
The most recent general population survey in Bosnia and Herzegovina was conducted in 2018 with the financial support of the IPA6 project. The situation in Bosnia and Herzegovina may have changed since 2018 and the data should therefore be interpreted with caution. The complete report can be downloaded from our Document library.
General population data reported to the EUDA by IPA beneficiaries can be found in the Source data section.
Drug use in the school population
Information about drug use in the school population is available from the series of ESPAD surveys among 15- to 16-year-old students. The most recent survey was conducted in Bosnia and Herzegovina in 2011. Data are available separately for the entities, Republika Srpska and Federation of Bosnia and Herzegovina.
Data from all ESPAD rounds can be accessed via the ESPAD Data Portal.
European Web Survey on Drugs
Bosnia and Herzegovina participated in the 2024 round of the European Web Survey on Drugs (EWSD). Although web surveys are not representative of the general population, when they are carefully conducted and combined with traditional data collection methods, they can help paint a more detailed, realistic and timely picture of patterns of drug use and drug markets in Europe and the European neighbourhood. As such, they are a key ingredient in the EUDA responsiveness to an ever-shifting drug problem.
GHB/GBL: gamma-hydroxybutyric acid/gamma-butyrolactone
NPS: new psychoactive substances
More information is available on the EWSD topic hub page. Further information on the findings from the EWSD for EU countries can Norway can be found in European Web Survey on Drugs 2024: top-level findings, 24 EU countries and Norway Further information on the findings from the EWSD for Western Balkan countries can be found in the factsheet European Web Survey on Drugs 2024: top level findings in the Western Balkans. For methodological information, please see EWSD 2024 methodology.
Problem drug use
'Problem drug use' is defined by the EUDA as 'injecting drug use or long duration / regular use of opioids, cocaine and/or amphetamines'. Existing estimates of problem drug use are often limited to opioid and poly-drug use. There have been no recent studies conducted in Bosnia and Herzegovina to estimate the size of the high-risk drug using population. A 2012 estimate of 12,500 people who use opioids or inject drugs is sometimes mentioned by experts, but is likely outdated, and the source of the data is not known.
Drug-related harms
Infectious diseases
The monitoring of drug-related infectious diseases among people who inject drugs (PWID) in Bosnia and Herzegovina historically relied on bio-behavioural surveys supported by the Global Fund to Fight AIDS, Tuberculosis and Malaria. No such survey has been conducted since 2015. Data on incidence (new cases attributed to injecting drug use) are available, but only information on HIV is reported to the European Centre for Disease Prevention and Control (ECDC).
Source: ECDC.
More data on the notification of infectious diseases can be downloaded in the Source data section.
Hospital emergencies
Data on hospital emergency presentations can provide a unique insight into acute health harms related to drug use. Euro-DEN Plus uses a sentinel centre model to collect data on emergency department presentations with acute drug toxicity. While the data do not necessarily provide a nationally representative picture, as only selected sites are included from participating countries, using a number of sentinel sites in significant locations provides useful information on the types of drugs involved in presentations to emergency services, and the trends at these sites.
Bosnia and Herzegovina does not report hospital emergencies data.
Drug-induced deaths
A drug‑induced death is a death resulting directly from the acute or chronic effects of drugs, including overdoses and poisonings, alone or in combination with other substances. Cases of drug-induced death are identified through the World Health Organization's International Classification of Diseases (ICD-10) codes in general mortality registries (GMR) or specific inclusion/exclusion rules in special mortality registries (SMR), such as forensic or police data.
Because some countries cannot fully apply these standards (e.g., due to coding limitations), data may be submitted in three categories:
- GMR (standard definition): Based on general mortality data;
- SMR (standard definition): Based on specialised registries;
- Other: When standard criteria cannot be fully applied
Data on drug-induced deaths are not available from Bosnia and Herzegovina.
Responses
Treatment provision
Bosnia and Herzegovina does not have a national register for specialised drug treatment, and data on people entering treatment are not available.
Opioid agonist treatment
Data on the provision of opioid agonist treatment (OAT) in Bosnia and Herzegovina are not available.
Harm reduction provision
Bosnia and Herzegovina does not have any needle and syringe programmes and has reported zero sterile syringes distributed per year since the beginning of the routine reporting to the EUDA in 2020.
Drug markets and crime
Drug law offences
This security indicator collects information on the number of offences or offenders/suspected offenders by type of offence and substance and describes the characteristics and trends of drug law offences, criminal and non-criminal. The collection of data may be challenging since it can be collected at different stages in the criminal justice system from different sources (e.g. from initial reports submitted by the police, cases of criminal offences submitted to the prosecutor) and information systems on drug law offences and offenders vary considerably between countries, especially as regards recording procedures, definitions and statistical units.
More data on drug law offences in IPA partners can be found in the Source data section
Drug seizures
This security indicator describes the characteristics and trends of drug seizures in order to improve our understanding of drug markets and supply-reduction activities. Data on drug seizures relate to all seizures during the year by all law enforcement agencies, mainly police and customs. All trend data, though, are subject to extraneous influences, such as changes in legislation, changes in police practices. There are no cases of double-counting between various agencies.
More data on drug seizures in IPA partners can be found in the Source data section.
More data on drug seizures in IPA partners can be found in the Source data section.
Purity/potency
This security indicator collects drug purity/potency data for some illicit substances including cannabis products, opioids and stimulants. The potency of cannabis products is defined as the delta-9-tetrahydrocannabinol (THC) content, where THC is the primary psychoactive constituent in cannabis. It is expressed in percent of THC. The laboratories and forensic science institutes undertaking quantitative drug determinations for law enforcement are the primary source of information. These facilities collect and register drug purity/potency data and related information.
More data on drug purity/potency in IPA partners can be found in the Source data section.
More data on drug purity/potency in IPA partners can be found in the Source data section.
Drug prices
This security indicator collects data on the prices of all types of drugs at retail, middle-market and wholesale levels. Street prices of cannabis, heroin, cocaine and amphetamine are provided in EUR per gram, LSD in EUR per unit/dose and MDMA/ecstasy in EUR per tablet. Data on prices come from a range of different sources, the comparability of which is not always known.
More data on drug prices in IPA partners can be found in the Source data section.
More data on drug prices in IPA partners can be found in the Source data section.
Links to other sources of information
Relevant EUDA publications
- EMCDDA trendspotter briefing – Illicit drug markets and supply in the Western Balkans: Impact of COVID-19
- EMCDDA trendspotter briefing: Impact of COVID-19 on drug use and drug services in Western Balkans
- Drug treatment systems in the Western Balkans: outcomes of a joint EMCDDA-UNODC survey of drug treatment facilities
- Drug use and its consequences in the Western Balkans 2006–14
- Drug-related health and security threats in the Western Balkans
- European Web Survey on Drugs 2024: top level findings in the Western Balkans
External data sources
- ECDC: HIV/AIDS surveillance in Europe 2025 - 2024 data
- UNODC Data Portal: UNODC data on several topics, including drugs trafficking and production and drug use and treatment
- UNODC Drugs Monitoring Platform: data on drug trafficking trends and on individual drugs seizures (IDS) dataset, which contains information on singular interception or apprehension
Source data
The data used to generate the infographics and charts on this page may be found below (CSV format). Additional information, metadata and methodological notes may be found in the IPA country data sheets background tables and source data entry in our Data catalogue.
| ID | Term |
|---|---|
| 1 | Bosnia and Herzegovina |
| 2 | Percentage (%) |
| 5 | EUR/gram |
| 7 | EUR/kilogram |
| 10 | Substance |
| 20 | European definition for general mortality register (GMR) |
| 30 | European definition for special mortality register (SMR) |
| 50 | converted from tablets to kg |
| 100 | Opioids (total) |
| 105 | Heroin |
| 107 | Heroin base |
| 108 | Heroin Hydrochloride |
| 110 | Cocaine (total) |
| 115 | Cocaine |
| 117 | Cocaine hydrochloride |
| 119 | Cocaine base (crack) |
| 120 | Stimulants other than cocaine (total) |
| 125 | Amphetamine |
| 130 | Hypnotics and sedatives (total) |
| 140 | Hallucinogens (total) |
| 145 | MDMA |
| 146 | MDMA and related MDx substances (ecstasy) |
| 150 | Volatile inhalants (total) |
| 160 | Cannabis (total) |
| 162 | Resin |
| 165 | Cannabis (herbal) |
| 166 | Herbal |
| 167 | Cannabis |
| 170 | Not known/missing |
| 180 | Grand total |
| 500 | All treatment entrants |
| 550 | Total OAT clients |
| 1000 | Kilograms |
| 1010 | Kilograms |
| 1020 | Number |
| 1030 | Retail |
| 1040 | Wholesale |
| 1100 | n |
| 5000 | ESPAD average |
| 5100 | Bosnia and Herzegovia |
| 5200 | Republika Srpska |
| 5300 | Federation of Bosnia and Herzegovina |
| 5400 | Bosnia and Hercegovina |
| ID | Term |
|---|---|
| 1 | Bosnia and Herzegovina |
| 2 | Bosnia and Herzegovia |
| 10 | Substance |
| 20 | European definition for General Mortality Register (GMR) |
| 30 | European definition for Special Mortality Register (SMR) |
| 50 | converted from tablets to kg |
| 100 | Opioids (total) |
| 105 | Heroin |
| 107 | Heroin base |
| 108 | Heroin Hydrochloride |
| 110 | Cocaine (total) |
| 115 | Cocaine |
| 117 | Cocaine Hydrochloride |
| 120 | Stimulants other than cocaine (total) |
| 125 | Amphetamine |
| 127 | Amphetamine (Tablet/Unit/dose) |
| 130 | Hypnotics and Sedatives (total) |
| 140 | Hallucinogens (total) |
| 150 | Volatile inhalants (total) |
| 160 | Cannabis (total) |
| 162 | Resin |
| 163 | Oil |
| 165 | Cannabis (herbal) |
| 166 | herbal |
| 167 | Cannabis |
| 168 | Cannabis (Oil) |
| 170 | Not known/missing |
| 180 | Grand Total |
| 500 | All treatment entrants |
| 1000 | Kg |
| 1010 | kg |
| 1015 | Kilograms |
| 1020 | Number |
| 1030 | Retail |
| 1040 | Wholesale |